The INFUSE - Anterior Myocardial Infarction (AMI) Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00976521 |
|
Recruitment Status :
Completed
First Posted : September 14, 2009
Results First Posted : July 8, 2013
Last Update Posted : July 8, 2013
|
Sponsor:
Atrium Medical Corporation
Information provided by (Responsible Party):
Atrium Medical Corporation
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the following arms:
- Local infusion of abciximab following thrombus aspiration
- Local infusion of abciximab and no thrombus aspiration
- No local infusion and thrombus aspiration
- No local infusion and no thrombus aspiration
In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Anterior Myocardial Infarction | Drug: Abciximab local infusion Other: No local infusion Procedure: Thrombus aspiration | Not Applicable |
The primary objective of the study is to demonstrate that among subjects undergoing primary PCI for anterior STEMI treated with a bivalirudin monotherapy anticoagulation strategy, the intracoronary infusion of an abciximab bolus with or without thrombus aspiration prior to stent implantation, compared to no infusion with or without thrombus aspiration (standard of care), results in 1) reduced infarct size measured by cardiac MRI at 30 days (range -7 days/+14 days; i.e., between 23 and 44 days), 2) reduce microvascular obstruction (MVO) by cardiac MRI at 5 + 2 days (i.e., between 3 and 7 days), 3) enhanced ST-segment resolution, 4) improved myocardial perfusion, 5) reduced thrombus burden and angiographic complications, and 6) no increase in major and minor bleeding.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 452 participants |
| Allocation: | Randomized |
| Intervention Model: | Factorial Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction |
| Study Start Date : | September 2009 |
| Actual Primary Completion Date : | February 2012 |
| Actual Study Completion Date : | April 2013 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Heart Attack
Drug Information available for:
Abciximab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Local infusion, thrombus aspiration
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
|
Drug: Abciximab local infusion
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter Procedure: Thrombus aspiration Thrombus aspiration |
|
Experimental: Local infusion, no aspiration
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
|
Drug: Abciximab local infusion
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter |
|
Active Comparator: No local infusion, thrombus aspiration
No local infusion of abciximab, thrombus aspiration.
|
Other: No local infusion
Intervention without local infusion Procedure: Thrombus aspiration Thrombus aspiration |
|
Active Comparator: No local infusion, no aspiration
No local infusion abciximab and no thrombus aspiration
|
Other: No local infusion
Intervention without local infusion |
Primary Outcome Measures :
- Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion [ Time Frame: 30 Days Post Index Procedure ]The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.
Secondary Outcome Measures :
- Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration [ Time Frame: 30 Days ]The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- The subject must be >18 years of age;
- Subject is experiencing clinical symptoms consistent with AMI (e.g., chest pain, arm pain, etc.,) >30 minutes duration and unresponsive to nitroglycerin;
- Anterior MI with ECG showing at least 1 mm of ST-segment elevation in 2 or more contiguous leads in V1-V4, or new (or presumably new) left bundle branch block;
- Anticipated symptom onset to balloon or aspiration time of ≤5 hours;
- The subject and his/her physician are willing to comply with specified follow-up evaluations;
- The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB)
- Infarct artery located in the proximal or mid left anterior descending coronary artery, with TIMI 0/1/2 flow at the time of initial diagnostic angiography (prior to wire passage);
- Based on coronary anatomy, PCI is indicated for revascularization;
- Only one epicardial coronary artery will be treated;
- Expected ability to deliver a ClearWay™ RX Infusion Catheter to the infarct lesion (absence of excessive tortuosity, diffuse disease or moderate/heavy calcification).
Key Exclusion Criteria:
- Prior myocardial infarction, or known prior systolic dysfunction (known ejection fraction <40% by any prior measure or regional wall motion abnormalities);
- An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first twelve months post enrollment;
- Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the AMI;
- Subject has previously undergone an angioplasty or stenting procedure in the left anterior descending artery;
- Definite planned use of aspiration, atherectomy, thrombectomy and/or distal protection catheters prior to PTCA or stent implantation (other than in subjects randomized to thrombus aspiration);
- Any contraindication to undergo MRI imaging.
- Multivessel intervention required during the index procedure (subjects may be enrolled if treatment of more than one lesion in the LAD or its branches is required, however) (planned staged procedures are permitted with strong recommendation to be performed after 30-day clinical and MRI endpoints are completed);
- Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the ClearWay™ RX Infusion Catheter or the Export® Aspiration Catheter;
- Features are present highly unfavorable for PCI;
- Target lesion is present within a bypass graft conduit;
- MI is due to thrombosis within or adjacent to a previously implanted stent;
- Left ventriculography demonstrates severe mitral regurgitation or a VSD;
- Unprotected left main stenosis >40% or that will require intervention
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00976521
Show 38 Study Locations
Sponsors and Collaborators
Atrium Medical Corporation
Investigators
| Principal Investigator: | Greg W Stone, MD | Columbia University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Atrium Medical Corporation |
| ClinicalTrials.gov Identifier: | NCT00976521 History of Changes |
| Other Study ID Numbers: |
901 |
| First Posted: | September 14, 2009 Key Record Dates |
| Results First Posted: | July 8, 2013 |
| Last Update Posted: | July 8, 2013 |
| Last Verified: | May 2013 |
Additional relevant MeSH terms:
|
Myocardial Infarction Anterior Wall Myocardial Infarction Infarction Ischemia Pathologic Processes Necrosis Myocardial Ischemia |
Heart Diseases Cardiovascular Diseases Vascular Diseases Abciximab Anticoagulants Platelet Aggregation Inhibitors |